ImMucin, a vaccine that targets a molecule present in 90 percent of all cancers, has been tested on humans for the first time, according to researchers who found that all the blood cancer patients tested in the trial had greater immunity to the disease after receiving the drug.
Results have yet to be formally published, but if the findings are confirmed in future trials then the vaccine could be on the market in six years.
The clinical trial was conducted at the Hadassah Medical Centre in Jerusalem and consisted of ten patients with multiple myeloma, a type of blood cancer that affects plasma cells in bone marrow, have now received the vaccine.
Researchers from the drug maker Vaxil Biotheraputics and Tel Aviv University said that seven of the patients who have finished treatment all had significantly greater immunity against cancer cells compared to before they were given the vaccine, and three of the patients in the study are now free of the condition.
“ImMucin generated a robust and specific immune response in all patients which was observed after only 2-4 doses of the vaccine out of a maximum of 12 doses. In some of the patients, preliminary signs of clinical efficacy were observed,” Vaxil Biotheraputics said in a statement announcing the vaccine’s promising results in its first human safety trial.
The prophylactic vaccine works by priming the body’s natural defense mechanisms to fight the disease, and aims to prevent cancer conditions, rather than attack cancer cells like many other treatments.
If you want read more Please click the below link